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The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality worldwide. The pathogen causing COVID-19, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can cause significant respiratory as well as multi-organ failure. Recently, studies have shown that patients with COVID-19 can also have ocular involvement. The most common ocular manifestation is conjunctivitis, with rates ranging from 0.8 to 31.6%.[@bib1]^,^[@bib2] In addition, there have been cases of retinal pathology reported in the setting of COVID-19, with hemorrhages and cotton wool spots on clinical exam, and hyper-reflective lesions of the inner retina on optical coherence tomography (OCT).[@bib3] However, the significance of these findings and possible relationship to other neurologic consequences of COVID-19 has yet to be determined.

In addition to primary ocular infection related to SARS-CoV-2, patients can develop indirect ocular complications related to COVID-19, especially those who are critically ill. ICU patients are at high risk for ocular surface diseases, such as exposure keratopathy, with rates of up to 40%.[@bib4] In ventilated patients with acute respiratory distress syndrome, prone positioning is often used to improve gas exchange. This practice not only can cause ocular surface disease, but can also be associated with increased intraocular pressure and ischemic optic neuropathy, threatening vision in at-risk patients.[@bib5]

Recently, children have been reported to develop a rare COVID-related inflammatory disease, now named Pediatric Multi-System Inflammatory Syndrome. One center in Italy recently saw a 30-fold increase in the incidence of Kawasaki-like disease in children over one month, most of whom tested positive for COVID-19 nasopharyngeal PCR or SARS-CoV-2 serology.[@bib6] These children exhibit symptoms similar to those seen in Kawasaki disease and toxic shock syndrome (TSS) and present with fever, conjunctivitis, abdominal pain, and rash.[@bib7] Here, we describe a case of an adult patient with recent diagnosis of COVID-19 who developed TSS.

2. Case report {#sec2}
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A 28-year-old female presented with rash, fever, and hypotension. Her past medical history was significant for end-stage renal disease, type 2 diabetes mellitus, and hypertension. She had no past ocular history. 19 days prior to this admission, she tested positive for COVID-19 and was admitted for hypoxic respiratory failure and required non-invasive positive pressure ventilation (NIPPV). At that time, she was treated with a course of hydroxychloroquine, steroids, and antibiotics. She was discharged 14 days later. 5 days following her discharge, she developed generalized weakness, poor appetite, fever, and desquamating rash and re-presented for evaluation. Upon arrival, she was febrile to 38.8 °C. Her blood pressure was 90/43. Her skin exam demonstrated diffuse erythematous and dusky colored plaques with bullae and superficial flaking, yellow crusting, scaling, and widespread erosions that involved 40% of her total body surface area. A gynecologic exam revealed no vulvar or vaginal involvement. Initial laboratory workup was notable for leukocytosis of 29,600/mm^3^. Respiratory virus panel, COVID-19 nasopharyngeal PCR, and blood cultures were negative. Chest x-ray revealed bibasilar infiltrates. Due to concern for septic shock, she was started on broad spectrum antibiotics (vancomycin, ceftazidime, and clindamycin).

Two days following her admission, she reported a burning sensation in both eyes and oral pain. Ophthalmic examination revealed that her visual acuity without pinhole was 20/40 in the right eye and 20/50 in the left eye. Her slit lamp exam was notable for areas of hyperpigmented skin with patchy lower eyelid desquamation and fluorescein staining involving less than 1/3 of the right eyelid margin and patchy lower left eyelid involvement with fluorescein staining involving the lateral 1/4 eyelid margin. Her conjunctiva exam revealed mild (1+) injection in both eyes with patchy palpebral conjunctival staining of the left eye. The remainder of her eye exam was unremarkable.

She was initiated on prednisolone acetate 1% eye drops every 2 hours in both eyes, preservative free artificial tears every 2 hours in both eyes, and erythromycin ointment four times a day in both eyes. On follow up 3 days later, she reported resolution of ocular symptoms. Repeat examination at that time was notable for only trace injection in both eyes without cicatrization. She was started on a taper of prednisolone acetate 1% eye drops and she did not report further ocular symptoms.

The patient\'s clinical presentation was initially suggestive of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) due to recent hydroxychloroquine use[@bib8]^,^[@bib9]; however, the superficial flaking of her skin raised concern for TSS. She underwent a punch biopsy which demonstrated "subcorneal split with parakeratosis, rare intraepidermal dyskeratosis, and superficial perivascular inflammation with neutrophils and eosinophils." The tissue sample was negative for a specific direct immunofluorescence pattern using monospecific fluorescein isothiocynanate (FITC)-conjugated anti-human IGG, IgA, IgM, C3, and fibrin. These histopathologic findings favored toxic shock syndrome and excluded Steven\'s Johnson syndrome and toxic epidermal necrolysis. However, the patient denied recent wounds, tampon use, or nasal packing, and there was no obvious infectious source on the patient\'s clinical exam or imaging tests. Thus, it is possible that her presentation of toxic shock may have instead been due to a primary immune-mediated post-COVID-19 phenomenon, similar to that described in pediatric patients.

3. Discussion {#sec3}
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TSS is a rare, multi-system, toxin-mediated disease that often presents with shock and progresses to multi-organ system failure. Diagnosis of TSS can be challenging as it is a clinical diagnosis. According to the Center for Disease Control, TSS is considered in a patient with the following clinical manifestations: fever, rash, desquamation, hypotension, and multisystem (three or more) involvement.[@bib10] Our patient presented with fever, rash, desquamation, and hypotension. Her symptoms also indicated multisystem involvement, such as generalized weakness, poor appetite, as well as mucous membrane involvement. Given her recent use of hydroxychloroquine which can be associated with SJS/TEN, she underwent a skin biopsy. While a biopsy is not necessary to diagnose TSS, it is often helpful to differentiate TSS from SJS/TEN due to its similarities in clinical presentations. For example, compared to SJS/TEN, TSS is more likely to demonstrate perivascular dermatitis and have neutrophil involvement.[@bib11]^,^[@bib12] The histopathologic findings of TSS can be specific and diagnostic for the condition,[@bib13] which can greatly aid in the diagnosis and treatment of patients.

The causes of TSS most commonly include toxin-producing strains of *Staphylococcus aureus* and *Streptococcus pyogenes*, which release bacterial toxins that trigger excessive T-cell activation and downstream cytokine storm.[@bib13] Staphylococcal TSS may present following influenza infection with symptoms of fever, abdominal pain, and myalgia early in disease, followed by confusion and lethargy. Desquamating rash occurs later, often around 10--21 days after disease onset.[@bib13] Other causes of staphylococcal TSS classically include wounds, prolonged tampon use or nasal packing. Streptococcal TSS, on the other hand, frequently presents following overt invasive soft-tissue infections such as necrotizing fasciitis or cellulitis.[@bib13]

Post-influenza TSS has been well-described in the literature, with the etiology attributed to a secondary bacterial pneumonia caused by *Staphylococcus aureus*. Impaired polymorphonuclear leukocyte chemotaxis and decreased tracheobronchial clearance following influenza infection increase the susceptibility of developing a secondary bacterial pneumonia.[@bib14]^,^[@bib15] The patient we present in this case developed symptoms of TSS approximately 19 days following her diagnosis of COVID-19. Secondary bacterial pneumonia has been reported in COVID-19 patients and it is conceivable that her presentation of toxic shock was secondary to a staphylococcal pneumonia.[@bib16]^,^[@bib17] Alternatively, SARS-CoV-2 can elicit a strong immune response in the host,[@bib6] and her TSS may have been a primary immune-mediated post-COVID-19 phenomenon, similar to that increasingly recognized in the pediatric population.

Conjunctival inflammation is an important feature of TSS and is almost always present early in the disease course.[@bib18]^,^[@bib19] The conjunctival inflammation in TSS is likely triggered by bacterial superantigens that cross mucosal barriers.[@bib20] Albeit less commonly, there have been rare reports of additional ocular consequences of TSS, including optic neuropathy, necrotizing anterior scleritis, and keratitis in streptococcal TSS, and vertical gaze palsy in the setting of staphylococcal TSS.[@bib21]^,^[@bib22]

4. Conclusion {#sec4}
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To our knowledge, this is first case of TSS in an adult following COVID-19 infection. The etiology may be due to a bacterial pneumonia from *Staphylococcus aureus*, though reports of Pediatric Multi-System Inflammatory Syndrome describe a similar illness associated with COVID-19 infection occurring in children. Additional research is needed to investigate the relationship between multi-system inflammatory conditions and COVID-19.
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